PrecisionLife has launched Biology Matters, a new podcast exploring how advances in biology, genomics, data science, and AI can help address one of healthcare's greatest challenges: chronic disease.
Poolbeg Pharma has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (CRS) patent application.
Pelago Bioscience has acquired RG Discovery. As a result of this acquisition, the largest Scandinavian CRO specializing in drug discovery has been created.
Explore Columbus Global's latest life science report featuring expert into the digital trends shaping the future of Pharma, MedTech and Biotech in 2026 and beyond.
Autolus Therapeutics today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product.
Poolbeg Pharma announces new research on two posters, by Poolbeg and The University of Manchester respectively, are being presented at the European Hematology Association Congress.
Poolbeg Pharma, a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred.
Discovery Park, Kent’s science and innovation hub, has launched the seventh edition of its Discovery Spark accelerator programme, welcoming 12 startups to its campus in Sandwich.
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease.
Chris Molloy on building on Parliament Day's momentum, TechBio's breakthrough week, the Oxford-to-Cambridge expansion, and driving global investor confidence at the Leadership Summit
Driven by world-class science and monumental funding, the UK TechBio sector is undergoing a profound paradigm shift – meet the innovative BIA members leading the charge
Engitix announced a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets driving liver fibrosis regression.
